Abstract 97P
Background
In the global LEAP-017 trial, treatment with lenvatinib + pembrolizumab (L + P) trended toward longer, but not significant, OS (HR: 0.83, 95% CI: 0.68-1.02, p-value: 0.0379) vs regorafenib or trifluridine–tipiracil (SOC), and toward more benefit in PFS and ORR. We present results of an exploratory analysis of patients (pts) enrolled in Asia combined with an extension cohort from China.
Methods
Eligible pts were aged ≥ 18 years, with confirmed unresectable, non-MSI-H/dMMR mCRC, and ≥1 prior line of therapy. Pts were allocated (1:1) to L (20 mg QD) + P (400 mg Q6W, up to 18 cycles) or SOC. Primary endpoint was OS. Secondary endpoints were PFS and ORR per RECIST 1.1 by BICR, and safety.
Results
At data cut-off (Feb 20, 2023), 237 pts were enrolled from Asia including China (N=100), Japan (N=63), Korea (N=41), and Taiwan (N=33). Overall, 118 pts received L + P, and 117 received SOC. In the Asia subgroup, after a median follow-up of 15.1 months (mo) and 15.2 mo, respectively, OS was longer with L + P vs SOC (median 13.4 vs 10.3 mo; HR: 0.63, 95% CI: 0.45-0.88), median PFS was 3.8 mo with L + P and 3.3 mo with SOC (HR: 0.78, 95% CI, 0.58-1.05), and ORR was 11.9% (95% CI, 6.6%- 19.1%) with L + P and 0% with SOC. In the China cohort, OS was longer with L + P vs SOC (median 14.9 vs 10.3 mo; HR: 0.61, 95% CI, 0.33-1.15), median PFS was 3.7 mo with L + P and 2.4 mo with SOC (HR: 1.18, 95% CI, 0.75-1.85), and ORR was 5.7% (95% CI, 1.2%-15.7%) with L + P and 0% with SOC. Grade ≥ 3 treatment-related AE rates were 58.5% and 49.6% with L + P and SOC, respectively, in the Asia subgroup, and 43.9% and 64.3%, respectively, in the Chinese extension cohort. One grade 5 treatment-related AE of pneumonitis occurred in the L + P arm in the Asia subgroup.
Conclusions
In this exploratory analysis from the Asia subgroup of LEAP-017 including the China extension, treatment with L + P vs SOC trended toward longer OS, consistent with the global trial. Trends towards improved PFS and ORR with L + P were also seen, consistent with the global trial; however, a similar trend in the PFS HR in the China subgroup was not observed. No new safety signals were observed.
Clinical trial identification
NCT04776148; first posted on February 26, 2021.
Editorial acknowledgement
Provided by Jose Casasvonas Nieves, PhD, an employee of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Legal entity responsible for the study
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Funding
Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
Disclosure
R. Xu: Financial Interests, Personal, Invited Speaker: BMS, MSD; Financial Interests, Personal, Advisory Board: Henrui, BeiGene, Astellas, Merck, Junshi. H. Teng: Financial Interests, Personal, Advisory Role: MSD Taiwan; Financial Interests, Personal, Speaker’s Bureau: MSD Taiwan. A. Takashima: Financial Interests, Institutional, Research Funding: MSD. T. Yang: Financial Interests, Institutional, Research Funding: MSD. T.W. Kim: Financial Interests, Institutional, Research Grant: Genentech; Financial Interests, Institutional, Research Funding: Merck. T. Kim: Financial Interests, Personal, Ownership Interest: IMBdx; Financial Interests, Institutional, Research Funding: MSD. J.O. Park: Financial Interests, Personal, Advisory Board: MedPacto, BMS (Celgene), Servier, MediRama, Adicet Bio, AstraZeneca, Merck Sereno, ImmuneOncia, Merck; Financial Interests, Personal, Other, Travel support for a poster presentation at ASCO GI 2023: Minneamrita Therapeutics LLC; Financial Interests, Personal, Research Grant, Clinical research grant: MedPacto, Servier, BMS (Celgene); Financial Interests, Personal, Research Grant: Eutilex, ABL Bio. S. Lee: Financial Interests, Institutional, Research Funding: MSD. K. Yeh: Financial Interests, Personal, Advisory Board: Daiichi Sankyo, PhytoHealth, Novartis, Ono, Merck, AstraZeneca; Non-Financial Interests, Personal, Member: American Society of Clinical Oncology, American Association for Cancer Research. T. Yoshino: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd.; Financial Interests, Personal, Other, Consultancy: Sumitomo Corp.; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical Co., Ltd, Sanofi K.K., MSD K.K., Taiho Pharmaceutical Co., Ltd., Molecular Health GmbH, Amgen K.K., Pfizer Japan Inc., Genomedia Inc., Sysmex Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., Roche Diagnostics K.K., FALCO Biosystems Ltd. R. Fu, R. Jain, D.E. Adelberg: Financial Interests, Personal, Full or part-time Employment: Merck. A. Kawazoe: Financial Interests, Personal, Advisory Board: Zymeworks, Merck & Co.; Financial Interests, Personal, Invited Speaker: Taiho, Daiichi Sankyo, Eli Lilly, Bristol Myers Squibb, Ono, All other authors have declared no conflicts of interest.
Resources from the same session
87TiP - Phase I expansion study of the tissue factor (TF)–targeting antibody-drug conjugate (ADC) XB002 as a single-agent and combination therapy in patients with advanced solid tumors (JEWEL-101)
Presenter: Mustafa Syed
Session: Poster Display
Resources:
Abstract
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract